Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs AMY 101 (Primary) ; AMY 101 (Primary)
- Indications Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Periodontitis; Renal failure
- Focus Adverse reactions; First in man
- Sponsors Amyndas Pharmaceuticals
- 13 Dec 2017 Results published in the Amyndas Pharmaceuticals Media Release
- 13 Dec 2017 Status changed from recruiting to completed, according to a Amyndas Pharmaceuticals media release.
- 26 Oct 2017 New trial record